A method for preparing and applying a polyclonal antibody against dengue virus type 2.
By using high-purity dengue virus type 2 strains as immunogens, combined with optimized animal immunization and antibody purification processes, high-titer, high-specificity polyclonal antibodies were prepared, solving the problems of antibody cross-reactivity and insufficient specificity in existing technologies, and realizing efficient virus diagnosis and research applications.
Patent Information
- Application Number
- CN202611240107.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-17
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, dengue virus type 2 antibodies vary in specificity and exhibit cross-reactivity between different serotypes, making it difficult to meet the needs of high-specificity diagnosis and basic research. Furthermore, recombinant proteins cannot completely mimic the natural structure of the virus, have weak immunogenicity, and cannot induce conformation-dependent neutralizing antibodies.
High-purity dengue virus type 2 strains were used as immunogens. High-titer, high-specificity polyclonal antibodies were prepared through optimized animal immunization strategies and a meticulous antibody purification process. The three-dimensional structure of the viral surface proteins was preserved, and cross-reaction with other serotypes was avoided. This included precise control of adjuvant selection, immunization dosage, procedure and time interval, as well as multi-step purification to remove impurities.
The prepared polyclonal antibodies can efficiently recognize natural conformational epitopes, possess high specificity and neutralizing activity, and are suitable for precision diagnosis and specific basic research. They solve the problem of cross-reactivity and achieve high antibody stability and batch consistency.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of modern bioimmunology and specifically relates to a method for preparing a specific antibody against dengue virus type 2 (DENV-2). Background Technology
[0002] Dengue virus (DENV) is an arbovirus transmitted by mosquitoes, belonging to the genus Flaviviridae in the family Flaviviridae. Dengue fever, caused by dengue virus, is the most common arbovirus infection worldwide, with 50-100 million cases annually. There are four serotypes of dengue virus (DENV-1 to DENV-4), with dengue virus type 2 (DENV-2) being the most pathogenic. Due to its high neurotoxicity and pathogenicity, DENV-2 is closely associated with the occurrence of severe dengue fever (DHF) and dengue shock syndrome (DSS). DENV-2 infection can cause severe systemic inflammatory responses, increased capillary permeability, internal bleeding, and other symptoms, with a mortality rate of 2.5%-5%. In addition, the association between DENV-2 and neurological complications (such as encephalitis and encephalopathy) is receiving increasing attention.
[0003] In-depth research on DENV-2 and the development of efficient diagnostic tools, therapeutics, and vaccines are of paramount public health importance. However, currently available or literature-reported dengue virus antibodies vary widely in specificity and exhibit cross-reactivity between different serotypes, making it difficult to meet the needs for highly specific diagnostics and basic research.
[0004] First, recombinant proteins cannot fully mimic the natural structure of the virus, particularly failing to form a multimeric conformation. This results in relatively weak immunogenicity and an inability to induce neutralizing antibodies against conformation-dependent neutralizing epitopes, limiting their application in neutralization experiments. Second, the four dengue virus serotypes share approximately 65%-75% sequence homology, making the prepared polyclonal antibodies prone to severe cross-reactivity. This leads to significant batch-to-batch antibody quality variations, a lack of standardized operating procedures, and a lack of preparation protocols specific to DENV-2. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention provides an innovative and systematic technical solution: using high-purity dengue virus type 2 strains as immunogens, and employing optimized animal immunization strategies, including adjuvant selection, immunization dosage, procedures and time intervals, and a refined antibody purification process, to prepare high-titer, high-specificity polyclonal antibodies capable of recognizing native conformational epitopes. Compared to methods based on recombinant proteins or VLPs, the native DENV-2 virus particles used in this invention retain the three-dimensional structure and post-translational modifications of the viral surface proteins, inducing a more comprehensive and robust immune response and generating broad-spectrum antibodies capable of recognizing multiple viral epitopes. This invention particularly emphasizes the specific recognition of dengue virus type 2, avoiding cross-reactivity with other serotypes (DENV-1, DENV-3, DENV-4). Specifically, it includes the following steps:
[0006] Step 1: Antigen preparation:
[0007] The standard clinical isolate of dengue virus type 2 (DENV-2) TR1751 was selected, amplified, purified to the required viral titer, and then used for later use.
[0008] Step 2: Immune response:
[0009] The host was immunized multiple times using the Freund's adjuvant system in conjunction with a gradient immunization program to induce a DENV-2 specific immune response.
[0010] Step 3: Serum Acquisition
[0011] During the immunization cycle, samples are collected periodically to detect antibody titers and cross-reactivity rates among multiple serotypes. Once the antibody titer reaches a plateau and the cross-reactivity rate is <5%, antiserum is obtained by sampling.
[0012] Step 4: Antibody purification:
[0013] After separating and purifying the antiserum, impurities were removed by adsorption of DENV-1, DENV-3, and DENV-4 viral particles to obtain highly specific DENV-2 polyclonal antibodies.
[0014] Step 5: Quality Control and Finalization
[0015] The purified antibody was subjected to quality testing to obtain a finished dengue virus type 2 specific polyclonal antibody. It is a natural conformation specific antibody that can specifically recognize multiple natural epitopes of dengue virus type 2, has no significant cross-reactivity with other serotypes, and has highly efficient DENV-2 neutralizing activity.
[0016] Further, the specific operation of step 1 is as follows: Select the standard clinical isolate of dengue virus type 2 (DENV-2) TR1751, inoculate it into the C6 / 36 mosquito cell line for expanded culture, and after 90% of the cells show typical cytopathic effects, collect the cell culture supernatant, filter, concentrate and purify it to obtain high-purity natural DENV-2 intact virus particle antigen, and measure the virus titer for later use.
[0017] Further, step 2 is specifically performed as follows: Select healthy SPF-grade BALB / c mice or New Zealand white rabbits as the immune host, use Freund's adjuvant system in conjunction with a gradient immunization program to perform multiple immunizations, control the immunization dose and injection method throughout the process, and achieve the induction of DENV-2 specific immune response.
[0018] Further, step 3 is specifically operated as follows: blood is collected from the host periodically during the immune cycle, and the antibody titer and cross-reactivity rate of multiple serotypes are detected by ELISA. After the antibody titer reaches the plateau phase and the cross-reactivity rate is <5%, the antiserum is finally obtained by blood collection and separation.
[0019] The blood collection criteria are as follows: blood is collected 3-5 days before each booster immunization. When the DENV-2 specific ELISA antibody titer is >1:100000 and the cross-reactivity rate with DENV-1, DENV-3, and DENV-4 is <5%, final blood is collected 7 days after the last immunization.
[0020] Further, step 4 is specifically performed as follows: the antiserum is subjected to ammonium sulfate precipitation for initial purification, protein A / G affinity chromatography for purification, and DENV-2 specific affinity chromatography for purification. Finally, cross-reactive antibodies are removed by adsorption of DENV-1, DENV-3, and DENV-4 viral particles to obtain highly specific DENV-2 polyclonal antibodies.
[0021] Further, step 5 involves the following steps: The purified antibody is tested for purity, concentration, specificity, and neutralizing activity to screen for qualified dengue virus type 2 specific polyclonal antibodies.
[0022] The quality control standards are as follows: antibody purity ≥95% as detected by SDS-PAGE electrophoresis, showing only characteristic bands of 50 kDa heavy chain and 25 kDa light chain; accurate and controllable antibody concentration as determined by BCA method; DENV-2 specific ELISA titer ≥1:500000; multi-serum cross-reactivity rate <5%; PRNT50 titer ≥300 as detected by plaque reduction neutralization assay, with no cross-neutralizing protective activity against DENV-1, DENV-3, and DENV-4.
[0023] This invention also includes the application of polyclonal antibodies, namely, applying dengue type 2 virus polyclonal antibodies prepared by any of the above methods to one or more of the following: the development of dengue type 2 virus precision diagnostic reagents, the study of viral pathogenic mechanisms, the research and evaluation of DENV-2 specific vaccines, and the study of the pathology of severe dengue fever.
[0024] The polyclonal antibody of this invention uses high-purity, natively conformed DENV-2 whole virus particles as the immunogen, maximizing the preservation of the native three-dimensional structure and post-translational modifications of the viral surface proteins. Through meticulous control of key steps such as viral antigen purification, immunization strategy design, adjuvant selection and application, and antiserum collection and antibody purification, the prepared antibody is ensured to have high specificity for DENV-2 and no cross-reactivity with other serotypes (DENV-1, DENV-3, DENV-4). Scientific, efficient, and reproducible standardized operating procedures ensure the stable preparation of high-specificity, high-titer antibodies.
[0025] Beneficial effects:
[0026] The antibody exhibits excellent performance and extremely high specificity. This invention uses natural, intact DENV-2 virus particles as the immunogen, fully preserving the virus's natural antigenic epitopes. Simultaneously, through a specific immunization procedure and multi-stage purification, the prepared antibody shows a cross-reactivity rate of <5% with DENV-1, DENV-3, and DENV-4, enabling precise identification of a single DENV-2 serotype. This completely solves the core problem of severe cross-reactivity in existing technologies, making it suitable for precision diagnostics and specific basic research scenarios.
[0027] The antibodies exhibit high activity and stable performance. The antibodies prepared in this invention have an ELISA specific titer ≥1:500,000 and a PRNT50 neutralizing titer ≥300. They possess excellent native conformation recognition ability and virus neutralizing activity, and can effectively identify viral conformation-dependent epitopes. They are suitable for high-end applications such as virus neutralization experiments and vaccine potency evaluation, and are far superior to antibodies prepared from traditional recombinant proteins.
[0028] The process is standardized and highly reproducible. This invention establishes a complete set of standardized operating procedures (SOPs) from virus culture, antigen purification, animal immunization, antibody purification to quality control. The parameters are precise and controllable, completely solving the problems of large batch variations and poor stability in traditional processes, and enabling stable mass production of high-quality antibodies.
[0029] The invention has a wide range of applications. The highly specific DENV-2 polyclonal antibody prepared in this invention can be used in multiple fields, including the development of rapid diagnostic reagents for dengue type II virus, research on viral pathogenesis and immune response, development and efficacy evaluation of DENV-2 specific vaccines, and research on the pathological mechanisms of severe dengue hemorrhagic fever. It has extremely high scientific research value and promising prospects for industrial transformation. Attached Figure Description
[0030] Figure 1 This is a viral amplification experiment diagram from an embodiment of the present invention.
[0031] Figure 2 This is a fluorescence quantitative PCR diagram from an embodiment of the present invention.
[0032] Figure 3 This is a PCR diagram of conserved sequences in an embodiment of the present invention.
[0033] Figure 4 This is a diagram showing the results of the plaque experiment in an embodiment of the present invention.
[0034] Figure 5A This is the key adjuvant used in the embodiments of the present invention.
[0035] Figure 5B These are healthy SPF-grade BALB / c mice used in the embodiments of this invention.
[0036] Figure 6 This is a graph showing the serum titer results of the antibodies in an embodiment of the present invention.
[0037] Figure 7 This is a diagram showing the purification results of the antibody in an embodiment of the present invention.
[0038] Figure 8 These are the antibody subtype detection results from the embodiments of the present invention.
[0039] Figure 9 These are microscopic morphological images showing the protective effect of the antibody on virus-infected cells in an embodiment of the present invention.
[0040] Figure 10 This is a graph showing the quantitative and statistical analysis of the protective effect of antibodies against virus-infected cells in this invention.
[0041] Figure 11 This is a graph showing the quantitative statistical results of the neutralizing protective efficacy of the polyclonal antibodies prepared in the embodiments of the present invention.
[0042] Figure 12 shows the affinity results of the antibody of the present invention. Detailed Implementation
[0043] The present invention will be further illustrated below with reference to the accompanying drawings and specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. After reading this invention, any modifications of the invention in various equivalent forms by those skilled in the art will fall within the scope defined by the appended claims.
[0044] Step 1: Antigen preparation, selection and culture of dengue virus type 2 strains
[0045] Strain selection: A representative clinical isolate of dengue virus type 2 was selected. The DENV-2 TR1751 strain is the latest standard reference strain isolated in China this year. It has the characteristics of strong genetic stability and high infectivity, making it an ideal choice for antibody preparation.
[0046] Virus culture: The mosquito cell line C6 / 36, the most commonly used cell line for culturing dengue virus, was used. The cells were cultured at 28°C and 5% CO2, with regular monitoring of cytopathic effect (CPE). C6 / 36 cells are highly sensitive to DENV-2 and produce high viral titers. When 70%-90% of the cells showed cytopathic effects, the cell culture supernatant was collected and frozen at -80°C for later use.
[0047] Virus purification: High-purity purification was performed using the PEG precipitation method. The specific method is as follows:
[0048] Preliminary concentration: The polyethylene glycol (PEG) 6000 / NaCl precipitation method is used for cost-effective purification. Through high-purity purification, impurities such as host cell components and culture medium components are removed to the maximum extent to ensure the specificity of the prepared antibody.
[0049] Viral titer determination: The titer of purified virus was accurately determined using the plaque forming unit (PFU) method or the TCID50 method. The PFU method is a standard method for quantifying viruses and accurately reflects their infectivity. The virus was diluted to the standard concentration with sterile PBS according to the predetermined immunoassay concentration.
[0050] Step 2: Immune response, animal immunization and strategy optimization (with special emphasis on DENV-2 specificity)
[0051] Host animal selection: SPF-grade BALB / c mice are preferred as the primary host animal because the IgG antibodies produced by mice have high homology with human IgG and are more likely to produce high-titer antibodies.
[0052] Immunoadjuvant: Freund's adjuvant system is used. To enhance specificity for DENV-2, a serotype-specific adjuvant containing heat-inactivated DENV-2-specific virus particles may be considered for the initial immunization.
[0053] Immunization schedule (key improvement): To ensure DENV-2 specificity, the following protocol was adopted: Primary immunization (day 0): 50 μg / animal of DENV-2 virus emulsified with CFA and injected intramuscularly into the hind leg. Second booster immunization (day 14): 50 μg / animal of the same strain emulsified with IFA and injected intramuscularly into the hind leg. Third booster immunization (day 28): 50 μg / animal of the same strain emulsified with IFA and injected intramuscularly into the hind leg. Fourth booster immunization (day 42): 50 μg / animal of the same strain emulsified with IFA and injected intramuscularly into the hind leg. Fifth booster immunization (day 56): 50 μg / animal of DENV-2 virus antigen, without adjuvant, injected intraperitoneally.
[0054] This procedure ensures continuous, highly specific stimulation to generate the maximum DENV-2-specific antibody response.
[0055] Cross-reactivity control: Before collecting antiserum, cross-reactivity was tested using other dengue virus serotypes (DENV-1, DENV-3, DENV-4). The specific recognition of the prepared antibody against DENV-2 was confirmed by serotype-specific ELISA, and the cross-reactivity rate should be <5%.
[0056] If necessary, adsorbed serum can be used to remove cross-reactive antibodies.
[0057] Step 3: Serum acquisition and purification of polyclonal antibodies (enhancing specificity).
[0058] Serum processing: Collected whole blood was placed at 37°C for 1 hour, then at 4°C overnight. After serum separation, it was centrifuged at 3000 rpm for 10 minutes.
[0059] Step 4: Antibody purification, quality control and specificity identification
[0060] Multi-step purification strategy (with particular emphasis on specific purification):
[0061] Ammonium sulfate precipitation, preliminary separation of IgG components
[0062] Protein A / G affinity chromatography efficiently captures all IgG antibodies in serum.
[0063] DENV-2 specific affinity chromatography—This method couples purified DENV-2 viral antigen to a chromatographic medium, capturing only antibodies that specifically recognize DENV-2. High-purity DENV-2 specific antibodies can be obtained by modifying the elution conditions.
[0064] Adsorption step – DENV-1, DENV-3, and DENV-4 viral particles adsorb potential cross-reactive antibodies to further improve specificity.
[0065] Step 5: Quality Control and Finalization
[0066] Quality control indicators include:
[0067] Purity: SDS-PAGE electrophoresis showed clear IgG heavy and light chain bands, purity ≥95%.
[0068] Concentration: BCA method or ultraviolet spectrophotometry (A280).
[0069] DENV-2 specific titer: ELISA method, using DENV-2-coated antigen serotype.
[0070] Specificity: When using DENV-1, DENV-3, and DENV-4 viruses for ELISA cross-reactivity detection, the cross-reactivity rate should be <5%.
[0071] Neutralizing activity: DENV-2 was tested using the Plaque Reduction Neutralization Test (PRNT) to determine its neutralizing activity. No cross-protection: DENV-2 should not provide protection against other serotypes of the virus.
[0072] Example
[0073] Preparation and purification of DENV-2 viral antigen
[0074] The standard dengue virus strain Tr1751 was inoculated into C6 / 36 mosquito cells and cultured at 28°C and 5% CO2. Cytopathic effects were observed daily, and when 70%-90% of the cells showed obvious cytopathic effects, the culture supernatant was collected and frozen at -80°C.
[0075] The supernatant was filtered through a 0.45 μm filter. Preliminary concentration was achieved by ultracentrifugation: 10000 × g, 4℃, 2 h. The precipitate was resuspended in PBS buffer and centrifuged using a 30%–60% sucrose density gradient: 100000 × g, 4℃, 3 h. The milky white viral band was aspirated and dialyzed against PBS. After determining the protein concentration, the concentration was adjusted to the level required for immunization. Figure 1 The image shown is an experimental diagram of viral amplification in this embodiment, illustrating the successful amplification of the virus. Figure 2 The image shown is a quantitative real-time PCR diagram from this embodiment, illustrating that the virus has good copying ability, as... Figure 3 The image shown is a PCR diagram of the conserved sequence in this embodiment, illustrating that the virus is the target virus. Figure 4 The figure shown is a result of the plaque experiment in this embodiment, illustrating the viral titer in this embodiment.
[0076] Immunization and serum collection of SPF-grade BALB / c mice
[0077] Five healthy SPF-grade BALB / c mice weighing 25-30 g were selected (e.g. Figure 5B(As shown). Serum was collected one week before immunization as a negative control serum.
[0078] The amount of purified DENV-2 viral antigen (50 μg / animal) can be adjusted according to body weight, generally in μg per kilogram of body weight, and an equal volume of Freund's complete adjuvant (CFA). Figure 5A As shown, emulsify thoroughly for 5 minutes, then inject 25 μg into the hind leg muscles at two injection sites.
[0079] The immunization procedure is as follows:
[0080] Day 14: Second immunization. DENV-2 antigen 50 μg / animal emulsified with IFA and injected intramuscularly into the hind leg.
[0081] Day 28: Third immunization, DENV-2 antigen 50 μg / animal emulsified with IFA, injected intramuscularly into the hind leg.
[0082] Day 42: Fourth immunization, DENV-2 antigen 50 μg / animal emulsified with IFA, injected intramuscularly into the hind leg.
[0083] Day 56: Fifth intraperitoneal booster immunization, DENV-2 antigen 50 μg / animal without adjuvant, intraperitoneal injection.
[0084] Three to five days before each booster immunization, a small amount of blood (approximately 5-10 ml) was collected from the tail of the mouse for serum separation. Antibody titers were detected using a DENV-2 specific ELISA, and cross-reactivity was simultaneously assessed using DENV-1, DENV-3, and DENV-4. When the DENV-2 antibody titer reached a plateau (>1:100,000) and cross-reactivity with other serotypes was <5%, final blood collection (approximately 40-50 ml) was performed seven days after the last booster immunization.
[0085] Blood was placed at 37°C for 1 hour, then at 4°C overnight. After the serum was fully separated, it was centrifuged at 3000 rpm for 15 minutes at 4°C. The supernatant serum was collected, aliquoted, and stored at -80°C.
[0086] Multi-step purification of polyclonal antibodies
[0087] Ammonium sulfate precipitation: Thaw the antiserum at 4°C and centrifuge at 10,000 rpm for 10 minutes. Collect the supernatant and slowly add an equal volume of saturated ammonium sulfate. Let stand at 4°C for 2 hours. Centrifuge at 10,000 rpm for 20 minutes, and resuspend the precipitate in a small amount of PBS.
[0088] Protein A / G affinity chromatography: Dialyze the resuspended protein against PBS at 4°C for at least 12 hours. Load the sample onto a pre-equilibrated protein A / G affinity chromatography column, wash with PBS until the baseline stabilizes, then elute with 0.1 M glycine-HCl (pH 2.7), collect the elution peak, and immediately neutralize to pH 7.0-7.4 with 1 M Tris-HCl (pH 9.0).
[0089] DENV-2 specific affinity chromatography: Purified DENV-2 viral particles are chemically coupled to an affinity chromatography medium to form a DENV-2 specific affinity column. Antibody samples purified by protein A / G are loaded onto the DENV-2 specific affinity column; only antibodies that specifically bind to DENV-2 are captured. The column is washed with PBS until the baseline stabilizes, then eluted with a gradually decreasing pH buffer, and the elution peak is collected.
[0090] Adsorption method for removing cross-reactive antibodies: To further improve specificity, DENV-1, DENV-3, and DENV-4 virus particles can be used to adsorb any cross-reactive antibodies that may be present in the sample. A mixture of DENV-1, 3, and 4 virus particles is added to the DENV-2 antibody sample and incubated at 4°C for 1-2 hours. Then, the sample is centrifuged at 12,000 rpm for 5 minutes, and the supernatant is collected as the final specific antibody.
[0091] Concentration and Displacement: The final antibody sample is concentrated by ultrafiltration and then displaced into PBS buffer or PBS containing 0.02% sodium azide. The final antibody concentration is determined by the BCA method. Figure 6 The figure shown is a serum titer result of the antibody in this embodiment, illustrating that the titer of the present invention has reached the expected level.
[0092] Quality assessment
[0093] Purity was checked using SDS-PAGE. Titer was detected using a DENV-2 specific ELISA, with cross-reactivity assays performed using DENV-1, 3, and 4. Neutralizing activity was detected using PRNT.
[0094] Expected results: The purity of the prepared polyclonal antibody is ≥95%; the DENV-2 specific ELISA titer is ≥1:500000; the cross-reactivity with DENV-1, 3, and 4 is <5%; the PRNT50 titer is ≥300; and it exhibits excellent DENV-2 specificity and neutralizing activity.
[0095] like Figure 7 The figure shown is a purification result diagram of the antibody in this embodiment, which illustrates that the antibody purification effect of the present invention has achieved the expected results. Figure 8The antibody subtype detection results of the antibody in this embodiment indicate that the produced polyclonal antibody has met expectations. This further demonstrates that the polyclonal antibody prepared in this invention can specifically recognize DENV-2, with cross-reactivity with DENV-1, DENV-3, and DENV-4 <5%, which is crucial in the diagnosis and research of dengue fever. It can be used for serotype-specific ELISA, RT-PCR-compatible antibodies, etc. The DENV-2 specific ELISA titer is ≥1:500,000, and the PRNT50 titer is ≥300, making it suitable for virus neutralization studies, vaccine evaluation, etc. The complete SOP ensures batch-to-batch consistency, guaranteeing the reproducibility of scientific research. It can be widely applied to: the development of rapid dengue diagnostic reagents, basic research on dengue type 2 virus, virological characteristics, pathogenic mechanisms, and immune responses. It can also be applied to the research and evaluation of DENV-2 specific vaccines, playing an important role in the mechanistic study of dengue hemorrhagic fever and dengue shock syndrome, especially the serotype-specific pathogenic mechanism of DENV-2.
[0096] Figure 9 The image shown is a diagram illustrating the protective effect of antibodies against virus-infected cells. This image is a set of microscopic photographs of cell morphology, which visually demonstrates the protective effect of antibodies by comparing the cell states of different treatment groups.
[0097] Figure A: Normal cell control group. The cells are in good growth condition, with intact morphology, typical spindle shape, tightly packed, forming a dense monolayer. This is what healthy cells should look like.
[0098] Figure B: Virus-infected control group. Cells were infected with DENV-2 virus, but no antibodies were added. Numerous cells became rounded, shrunken, and intercellular spaces widened, exhibiting a clear cytopathic effect (CPE). This indicates that the virus successfully infected and damaged the cells.
[0099] Figures C, D, E, F, and G: Protection groups with different antibody concentrations. Cells in these groups were infected with the virus and then treated with different concentrations of the polyclonal antibodies prepared in this invention. It can be observed that the degree of protection received by the cells varies with the antibody concentration. Compared to Figure B, the cytopathic effect in these groups was significantly reduced, and more cells maintained their normal spindle shape. This provides direct evidence that the antibodies can neutralize the virus and protect cells from damage.
[0100] Figure H: The group with complete protection from high-concentration antibodies or another control. The cell morphology in the figure is very similar to the normal cells in Figure A, with almost no lesions, indicating that the antibody provides near-complete protection under these conditions.
[0101] Figure 9 Qualitative evidence demonstrates that the antibody of this invention can effectively inhibit cytopathic effects caused by DENV-2 virus.
[0102] Figure 10 The figure shown is a quantitative statistical graph of antibody protective efficacy. The p-value demonstrates that the protective effect of the antibody is highly statistically significant. This graph, using precise data and statistical analysis, quantitatively confirms that the antibody of this invention can significantly reduce viral infection levels, and its effect is superior to the control group.
[0103] Figure 11 The graph shown is a dose-response relationship diagram of antibody neutralizing efficacy. This curve further analyzes the neutralizing ability of antibodies, demonstrating the relationship between antibody concentration and neutralizing effect. When the antibody concentration is high, the relative neutralization rate is close to 100%, indicating that the antibody can almost completely neutralize the virus. As the antibody is continuously diluted, the neutralization rate gradually decreases. When the antibody concentration is too low, the neutralization rate approaches 0, and the protective effect is lost. This graph not only proves the effectiveness of the antibody but also accurately describes how its efficacy changes with concentration, making it a key indicator for evaluating the performance of an antibody drug or reagent.
[0104] Figure 12 shows the affinity results of the antibody of the present invention. The results indicate that the antibody of the present invention has good affinity for the virus.
[0105] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the embodiments should be considered in all respects as exemplary and non-limiting, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, all variations falling within the meaning and scope of equivalents of the claims are intended to be included within the present invention. No reference numerals in the claims should be construed as limiting the scope of the claims.
[0106] Furthermore, it should be understood that although this specification describes embodiments, not every embodiment contains only one independent technical solution. This narrative style is merely for clarity. Those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.
Claims
1. A method for preparing dengue type 2 virus polyclonal antibody from dengue type 2 virus strain, characterized by, Includes the following steps: Step 1: Antigen preparation: The standard clinical isolate of dengue virus type 2 (DENV-2) TR1751 was selected, amplified, purified to the required viral titer, and then used for later use. Step 2: Immune response: The host was immunized multiple times using the Freund's adjuvant system in conjunction with a gradient immunization program to induce a DENV-2 specific immune response. Step 3: Serum Acquisition During the immunization cycle, samples are collected periodically to detect antibody titers and cross-reactivity rates among multiple serotypes. Antiserum is collected after the antibody titer reaches a plateau and the cross-reactivity rate is <5%. Step 4: Antibody purification: After separating and purifying the antiserum, impurities were removed by adsorption of DENV-1, DENV-3, and DENV-4 viral particles to obtain highly specific DENV-2 polyclonal antibodies. Step 5: Quality Control and Finalization The purified antibody was subjected to quality testing to obtain a finished dengue virus type 2 specific polyclonal antibody. The antibody is a natural conformation specific antibody that specifically recognizes multiple natural epitopes of dengue virus type 2, has no cross-reactivity with other serotypes, and has highly efficient DENV-2 neutralizing activity.
2. The method of claim 1, wherein, Step 1 is performed as follows: The standard clinical isolate of dengue virus type 2 (DENV-2) TR1751 was selected and inoculated into the C6 / 36 mosquito cell line for expanded culture. After 70%–90% of the cells showed typical cytopathic effects, the cell culture supernatant was collected, filtered, concentrated, and purified to obtain high-purity natural DENV-2 intact virus particle antigen. The virus titer was then determined for later use.
3. The method of claim 1, wherein, Step 2 is performed as follows: Healthy SPF-grade BALB / c mice or New Zealand white rabbits were selected as the immunization hosts. Multiple immunizations were performed using Freund's adjuvant system in conjunction with a gradient immunization program. The immunization dose and injection method were controlled throughout the process to achieve the induction of a DENV-2 specific immune response.
4. The method of claim 1, wherein, Step 3 is performed as follows: Blood samples were collected from the host periodically during the immune cycle, and antibody titers and cross-reactivity rates of multiple serotypes were detected by ELISA. Once the antibody titer reached a plateau and the cross-reactivity rate was <5%, antiserum was finally obtained by blood collection and separation. The blood collection criteria are as follows: blood is collected 3 to 5 days before each booster immunization. When the DENV-2 specific ELISA antibody titer is >1:100000 and the cross-reactivity rate with DENV-1, DENV-3, and DENV-4 is <5%, final blood is collected 7 days after the last immunization.
5. The method of claim 1, wherein, Step 4 is performed as follows: The antiserum was initially purified by ammonium sulfate precipitation, purified by protein A / G affinity chromatography, and purified by DENV-2 specific affinity chromatography. Finally, cross-reactive antibodies were removed by adsorption of DENV-1, DENV-3, and DENV-4 viral particles to obtain highly specific DENV-2 polyclonal antibodies.
6. The method of claim 1, wherein, Step 5 is performed as follows: The purified antibodies were tested for purity, concentration, specificity, and neutralizing activity to screen for qualified dengue virus type 2 specific polyclonal antibodies. The quality control standard is: antibody purity ≥95% as detected by SDS-PAGE electrophoresis, showing only characteristic bands of 50 kDa heavy chain and 25 kDa light chain; The BCA method allows for precise and controllable determination of antibody concentration. DENV-2 specific ELISA titer ≥1:500000; multi-serum cross-reactivity rate <5%; plaque reduction neutralization assay PRNT detection PRNT50 titer ≥300, and no cross-neutralizing protective activity against DENV-1, DENV-3, and DENV-4.
7. Use of a polyclonal antibody, characterized in that The dengue virus polyclonal antibody prepared by the method described in any of the preceding claims may be applied to one or more of the following: the development of dengue virus precision diagnostic reagents, the study of viral pathogenesis mechanisms, the research and evaluation of DENV-2 specific vaccines, and the study of the pathology of severe dengue fever.
